<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>A Phase 3 Trial of brepocitinib in dermatomyositis</title>
  </titleInfo>
  <name type="personal">
    <namePart>Lundberg, Ingrid E.</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">pe</placeTerm>
    </place>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">spa</languageTerm>
  </language>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="marcform">print</form>
    <extent>páginas: 1953-1955</extent>
  </physicalDescription>
  <abstract>Dermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality. Treatment of myositis is based on off-label use of high doses of glucocorticoids, usually over long periods of time, in combination with immune-modulating agents and physical exercise. However, the outcome is often disappointing, with persisting inflammation and recurrent flares.</abstract>
  <subject>
    <topic>ALERGIA</topic>
  </subject>
  <subject>
    <topic>INMUNOLOGÍA GENERAL</topic>
  </subject>
  <subject>
    <topic>ENFERMEDAD AUTOINMUNE</topic>
  </subject>
  <subject>
    <topic>DERMATOLOGÍA GENERAL</topic>
  </subject>
  <subject>
    <topic>ENFERMEDAD PULMONAR INTERSTICIAL</topic>
  </subject>
  <subject>
    <topic>ENFERMEDAD NEUROMUSCULAR</topic>
  </subject>
  <subject>
    <topic>NEUROLOGÍA</topic>
  </subject>
  <subject>
    <topic>NEUROCIRUGÍA</topic>
  </subject>
  <subject>
    <topic>CÉLULAS T</topic>
  </subject>
  <relatedItem type="host">
    <titleInfo>
      <title>The New England Journal of Medicine</title>
    </titleInfo>
    <originInfo>
      <publisher>Massachusetts NEJM Group</publisher>
    </originInfo>
    <identifier>NEJM014</identifier>
    <identifier type="issn">0028-4793</identifier>
    <identifier type="local">ESSALUD</identifier>
  </relatedItem>
  <recordInfo>
    <recordContentSource authority="marcorg">BMG</recordContentSource>
    <recordCreationDate encoding="marc">      </recordCreationDate>
    <recordChangeDate encoding="iso8601">20260902163508.0</recordChangeDate>
    <recordIdentifier>ESSALUD</recordIdentifier>
  </recordInfo>
</mods>
